WDR5 inhibitors and modulators
Grant
US12577227B2
Kind: B2
Mar 17, 2026
Assignee
Vanderbilt University
Inventors
Taekyu Lee, Changho Han, Jonathan J. Mills, Kevin B. Teuscher, Jianhua Tian, Kenneth M. Meyers, Somenath Chowdhury, Stephen W. Fesik
Abstract
Quinazolin-4(3H)-one, 2,3-dihydroquinazolin-4(1H)-one, 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one, and 3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
CPC Classifications
C07D 401/14
C07D 403/06
C07D 403/12
C07D 403/14
C07D 413/06
C07D 413/12
C07D 413/14
C07D 417/14
C07D 471/04
A61P 35/00
Filing Date
2020-06-04
Application No.
17613717
Claims
18